FDA Unveils Draft Plan For New Benefit-Risk Framework
The U.S. Food and Drug Administration on Thursday released a draft five-year plan on developing a strong benefit-risk framework for reviewers to use during the drug and biologic review process, a...To view the full article, register now.
Already a subscriber? Click here to view full article